Breakthrough lung cancer drug helps clinical trial patient

March 06, 2015

A breakthrough drug for treating the most common type of lung cancer was just approved by the Food and Drug Administration ahead of schedule following two successful clinical trials, including one that involved patients at Providence Cancer Center in Portland.

Providence studies new therapy for patients with curable breast cancer

October 22, 2013
Providence Cancer Center is the only site in Oregon to open the KATHERINE study (NSABP B-50-I), evaluating the efficacy and safety of trastuzumab emtansine (Kadcyla) versus trastuzumab (Herceptin) as adjuvant (postoperative) therapy for breast cancer.

Providence Cancer Center first in nation to offer unique trial treatment for lymphoma patients

May 21, 2013

People with B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia have a unique opportunity to participate in groundbreaking research at Providence Cancer Center.

Early-phase clinical trials open new opportunities

January 16, 2013

Providence's involvement with the International Immuno-Oncology Network, along with other early-phase studies, is broadening treatment options for patients with advanced cancers.

Providence Cancer Center recognized for commitment to quality and excellence

September 28, 2012

Providence is the only cancer facility in Oregon to receive QOPI certification.

Providence selected for nationwide immunotherapy network

October 24, 2011

Providence Cancer Center is among North America's top research institutions invited to join the national Cancer Immunotherapy Trials Network.

Providence cancer drug trial wins FDA approval

April 11, 2011

Ipilimumab is the first drug shown to extend survival in patients with late-stage melanoma.